Souzan Sanati Selected Research

Neoplasms (Cancer)

1/2024	Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial.
8/2021	Early Assessment Window for Predicting Breast Cancer Neoadjuvant Therapy using Biomarkers, Ultrasound, and Diffuse Optical Tomography.
1/2019	Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast.
11/2017	Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
11/2017	A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer.
4/2017	Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
1/2017	Proteogenomic integration reveals therapeutic targets in breast cancer xenografts.
12/2016	Axillary Ultrasound Accurately Excludes Clinically Significant Lymph Node Disease in Patients With Early Stage Breast Cancer.
1/2016	Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast.
10/2009	Gene expression profiles of ductal versus acinar adenocarcinoma of the prostate.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Souzan Sanati Research Topics

Disease

12	Breast Neoplasms (Breast Cancer) 01/2024 - 03/2005
12	Neoplasms (Cancer) 01/2024 - 10/2004
5	Pathologic Complete Response 01/2024 - 02/2016
3	Neoplasm Metastasis (Metastasis) 01/2020 - 01/2019
2	Triple Negative Breast Neoplasms 12/2021 - 01/2020
1	Residual Neoplasm 01/2024
1	Inflammation (Inflammations) 01/2020
1	Extranodal Extension 01/2020
1	Neuroendocrine Carcinoma 01/2019
1	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2019
1	Microsatellite Instability 01/2019
1	Fat Necrosis 01/2018
1	Phyllodes Tumor (Cystosarcoma Phylloides) 01/2016
1	Adenocarcinoma 10/2009
1	Acinar Cell Carcinoma 10/2009
1	Primitive Neuroectodermal Tumors (PNET) 06/2007
1	Pathologic Constriction (Stenosis) 06/2005
1	Wounds and Injuries (Trauma) 03/2005

Drug/Important Bio-Agent (IBA)

5	Anastrozole (Arimidex)FDA LinkGeneric 01/2024 - 04/2017
5	Estrogen ReceptorsIBA 01/2024 - 04/2017
5	Biomarkers (Surrogate Marker)IBA 08/2021 - 01/2016
4	Proteins (Proteins, Gene)FDA Link 04/2017 - 10/2009
2	RNA (Ribonucleic Acid)IBA 01/2024 - 10/2009
2	Cyclin-Dependent Kinase 4IBA 11/2017 - 08/2017
2	palbociclibIBA 11/2017 - 08/2017
2	Goserelin (Zoladex)FDA Link 11/2017 - 08/2017
2	Coloring Agents (Dyes)IBA 06/2007 - 10/2004
1	Fulvestrant (Faslodex)FDA Link 01/2024
1	Phenobarbital (Luminal)FDA Link 01/2024
1	Tumor Biomarkers (Tumor Markers)IBA 08/2021
1	N-acetyltalosaminuronic acid (NAT)IBA 08/2021
1	Dihydrotachysterol (AT 10)IBA 01/2020
1	B7-H1 AntigenIBA 01/2019
1	CateninsIBA 01/2019
1	Immune Checkpoint InhibitorsIBA 01/2019
1	thymidine kinase 1IBA 11/2017
1	Messenger RNA (mRNA)IBA 11/2017
1	Prednisone (Sone)FDA LinkGeneric 11/2017
1	MK 2206IBA 11/2017
1	Estrogens (Estrogen)FDA Link 11/2017
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 08/2017
1	exemestane (Aromasin)FDA Link 04/2017
1	Aromatase InhibitorsIBA 04/2017
1	Letrozole (Femara)FDA LinkGeneric 04/2017
1	ProteomeIBA 01/2017
1	Prolactin Receptors (Prolactin Receptor)IBA 10/2009
1	Periodic AcidIBA 06/2007
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 06/2005
1	Hormones (Hormone)IBA 03/2005

Therapy/Procedure

6	Neoadjuvant Therapy 01/2024 - 02/2016
6	Therapeutics 01/2019 - 01/2016
1	Lymph Node Excision (Lymph Node Dissection) 01/2020
1	Brachytherapy 01/2018
1	Adjuvant Chemotherapy 09/2017
1	Drug Therapy (Chemotherapy) 04/2017
1	Lasers (Laser) 10/2009